Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
Total Valuation
Allogene Therapeutics has a market cap or net worth of $257.38M. The enterprise value is $61.27M.
Market Cap$257.38M
Enterprise Value$61.27M
Share Statistics
Allogene Therapeutics has 221,881,030 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding221,881,030
Owned by Insiders10.60%
Owned by Institutions46.52%
Financial Efficiency
Allogene Therapeutics’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -52.56%.
Return on Equity (ROE)-0.61
Return on Assets (ROA)-0.47
Return on Invested Capital (ROIC)-52.56%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee97.35
Profits Per Employee-1.14M
Employee Count226
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Allogene Therapeutics is ―. Allogene Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value0.98
Price to FCF―
Price to Operating Cash Flow-1.42
PEG Ratio―
Income Statement
In the last 12 months, Allogene Therapeutics had revenue of 22.00K and earned -257.59M in profits. Earnings per share was -1.32.
Revenue22.00K
Gross Profit22.00K
Operating Income-273.20M
Pretax Income-257.15M
Net Income-257.59M
EBITDA-243.33M
Earnings Per Share (EPS)-1.32
Cash Flow
In the last 12 months, operating cash flow was -172.77M and capital expenditures -829.00K, giving a free cash flow of -173.60M billion.
Operating Cash Flow-172.77M
Free Cash Flow-173.60M
Free Cash Flow per Share-0.78
Dividends & Yields
Allogene Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.09
52-Week Price Change-54.86%
50-Day Moving Average1.21
200-Day Moving Average1.65
Relative Strength Index (RSI)50.27
Average Volume (3m)4.99M
Important Dates
Allogene Therapeutics upcoming earnings date is Oct 30, 2025, Before Open (Confirmed).
Last Earnings DateAug 13, 2025
Next Earnings DateOct 30, 2025
Ex-Dividend Date―
Financial Position
Allogene Therapeutics as a current ratio of 8.54, with Debt / Equity ratio of 23.00%
Current Ratio8.54
Quick Ratio8.54
Debt to Market Cap0.00
Net Debt to EBITDA-0.06
Interest Coverage Ratio-1.51K
Taxes
In the past 12 months, Allogene Therapeutics has paid 443.00K in taxes.
Income Tax443.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Allogene Therapeutics EV to EBITDA ratio is -1.77, with an EV/FCF ratio of -2.14.
EV to Sales19.57K
EV to EBITDA-1.77
EV to Free Cash Flow-2.14
EV to Operating Cash Flow-2.15
Balance Sheet
Allogene Therapeutics has $273.12M in cash and marketable securities with $79.24M in debt, giving a net cash position of -$193.88M billion.
Cash & Marketable Securities$273.12M
Total Debt$79.24M
Net Cash-$193.88M
Net Cash Per Share-$0.87
Tangible Book Value Per Share$2.17
Margins
Gross margin is 0.00%, with operating margin of -1241813.64%, and net profit margin of -1170863.64%.
Gross Margin0.00%
Operating Margin-1241813.64%
Pretax Margin-1168850.00%
Net Profit Margin-1170863.64%
EBITDA Margin-1106031.82%
EBIT Margin-1168027.27%
Analyst Forecast
The average price target for Allogene Therapeutics is $7.44, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$7.44
Price Target Upside541.38% Upside
Analyst ConsensusModerate Buy
Analyst Count14
Revenue Growth Forecast-100.00%
EPS Growth Forecast30.91%